Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension
Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma; Ocular Hypertension
Intervention: brimonidine (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Allergan
Summary
This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or
ocular hypertension
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: lowering of intraocular pressure
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ocular hypertension or glaucoma in both eyes
- currently treated with brimonidine
- requires IOP-lowering therapy in both eyes
Exclusion Criteria:
- uncontrolled systemic disease
- known allergy or sensitivity to brimonidine
Locations and Contacts
Additional Information
Link to Clinical Trial Results
Starting date: January 2005
Last updated: May 27, 2011
|
